Case Report: Clinical and Serological Hallmarks of Cytokine Release Syndrome in a Canine B Cell Lymphoma Patient Treated With Autologous CAR-T Cells
Open Access
- 11 July 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Veterinary Science
- Vol. 9, 824982
Abstract
Background: Chimeric antigen receptor-T (CAR-T) cells have transformed the treatment of human B cell malignancies. With the advent of CAR-T therapy, specific and in some cases severe toxicities have been documented with cytokine release syndrome (CRS) being the most frequently reported. As dogs develop tumors spontaneously and in an immunocompetent setting, they provide a unique translational opportunity to further investigate the activity and toxicities associated with CAR-T therapy. Although various adoptive cellular therapy (ACT) trials have been documented and several more are ongoing in canine oncology, CRS has not been comprehensively described in canine cancer patients.Case Presentation: Here we present the clinical and serologic changes in a dog treated with autologous CAR-T for relapsed B cell lymphoma that presented with lethargy and fever 3 days following CAR-T. Multiplexed serum cytokine profiling revealed increases in key cytokines implicated in human CRS including IL-6, MCP-1, IFNγ and IL-10 at or shortly after peak CAR-T levels in vivo.Conclusion: The observations noted in this case report are consistent with CRS development following CAR-T therapy in a canine patient. The dog represents a compelling model to study the pathophysiology of CRS and pre-clinically screen novel therapeutics to prevent and treat this life-threatening condition in the setting of a complex and naturally evolved immune system.Keywords
Funding Information
- National Institutes of Health
This publication has 27 references indexed in Scilit:
- Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology PatientsMolecular Therapy, 2018
- Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapyBlood, 2017
- Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor MicroenvironmentCancer Cell, 2017
- Feasibility and Safety of RNA-transfected CD20-specific Chimeric Antigen Receptor T Cells in Dogs with Spontaneous B Cell LymphomaMolecular Therapy, 2016
- Engineered T cells: the promise and challenges of cancer immunotherapyNature Reviews Cancer, 2016
- Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic LeukemiaCancer Discovery, 2016
- Perspectives from man’s best friend: National Academy of Medicine’s Workshop on Comparative OncologyScience Translational Medicine, 2016
- Cancer immunology and canine malignant melanoma: A comparative reviewVeterinary Immunology and Immunopathology, 2016
- Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging TherapiesThe Cancer Journal, 2014
- Establishment and characterization of a novel canine B-cell line derived from a spontaneously occurring diffuse large cell lymphomaLeukemia Research, 2010